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 2 
What gives a protein the ability to sensitise, to be an allergen, in particular a food allergen, 33 
is not well understood. Previously we reported that natural nut lipids were necessary for 34 
sensitization and that Natural Killer T Cells (NKTs) must play a critical role in the 35 
development of Brazil nut –allergic responses. 36 
A major bottleneck in further understanding the interaction of nut natural lipids with the 37 
cells of the human immune system is the lack of well-characterized lipid responsive 38 
human cell lines. In the present study, we engineered human T-cell receptor (TCR) 39 
sequences TRAV10 (clone J3N.5T) and TRBV25 (clone BM2a.t) responsive to -GalCer 40 
into a stable murine iNKT hybridoma cell line. This system has shown to be problematic 41 
as far as expression of new and functional human TCR sequences is concerned. To 42 
overcome this limitation, we then show that the expression of human TCR sequences has 43 
been achieved using a bidirectional promoter on a plasmids or a lentivirus system. This 44 
system employed murine or human stable DC cell lines as lipid presenting cells and a 45 
stable T cell line as a surrogate system. Further, we show that the commercial human 46 
Jurkat cell line containing an inducible secreted luciferase reporter construct regulated by 47 
human NFAT binding sites was functional and can be used for a transient expression of 48 
human TCRs in a lipid screening program. We also show that transfection efficiencies 49 
were improved using the lentivirus polycistronic constructs containing the P2A sequence 50 
in a TCR / null cell line (Jurkat 76). These results suggest that the mis-pairing of the 51 
endogenous / TCR during ER folding in the presence of the new human TCR 52 
sequences could be impairing the functionality of the TCR lipid receptors. This will help 53 
towards a surrogate system to express functional human lipid binding TCR sequences. 54 
These are important first steps in the establishment of human cell-specific lipid responsive 55 
libraries for the study of natural lipid substances. 56 
 57 
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 59 
 60 
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Introduction 63 
What makes a protein an allergen with respect to the ability to sensitise and, in 64 
particular a food allergen, is not well understood. Previously Kean et al reported that 65 
SFA8, the 2S albumin from sunflower, and not the major nut allergen Ber e 1 was able 66 
to polarize dendritic and T helper (Th) cell responses in mice with production of IL-12 67 
p40 and TNF-alpha. Transcription analysis showed increased Th1 transcrition factor 68 
T-bet with respect to both proteins, but some Th2  GATA-3 with respect to Ber e 1 69 
(Kean et al., 2006). Subsequently, it was shown that Brazil nut lipids were required for 70 
sensitization with Ber e 1 (Dearman et al., 2007) and that one particular complex lipid 71 
fraction (lipid C) was able to induce specific Ber e 1 anaphylactic antibodies in naïve 72 
animals. Subsequently, in kinetic experiments we have also shown that Ber e 1 can 73 
indeed accommodate one lipid molecule (stoichiometry 1:1) with Kd of 5.6±0.1 µM 74 
(Mirotti et al., 2013; Rundqvist et al., 2012). The requirement for natural lipids from 75 
nuts as a critical component for the intrinsic allergenicity of Ber e 1 was further 76 
demonstrated when human T-cell lines derived from nut allergic patients were shown 77 
to produce IL-4 to Ber/lipid C in a CD1d dose dependent manner. Ja18 and CD1 knock 78 
out experiments further implicated Natural Killer T Cells (NKTs) in the response 79 
(Mirotti, Florsheim et al. 2013). Altogether, these results illustrate the essential role of 80 
the natural lipid fraction in nut protein sensitization and strongly suggest that NKTs  81 
play a critical role in the development of Brazil nut –allergic response (Mirotti et al., 82 
2013).   83 
 84 
NKT cells are unique lymphocyte subpopulations characterized by co-expression of 85 
surface markers from conventional NK and T cells. NKTs make up 0.01-2 % of human 86 
peripheral blood mononuclear cells and have been shown to be important in all 87 
aspects of immunity such as development, regulation of autoimmune, allergic, 88 
infectious and neoplastic responses (Godfrey et al., 2015; O’Konek et al., 2012; 89 
Taniguchi et al., 2003). In response to T-cell receptor (TCR) engagement NKTs rapidly 90 
produce cytokines involved in the activation of dendritic cells (DCs), NK cells, 91 
macrophages, B cells and conventional T cells amongst others. NKTs, via TCR 92 
engagement, can recognize lipid antigens that are presented by the nonclassical MHC 93 
I-like CD1 receptors expressed on the surface of antigen presenting cells (APCs), 94 
which is significantly different from T cells (de Jong, 2015). Lipid antigens presented 95 
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via CD1 generally respond to changes in extracellular environment (Dowds et al., 96 
2014). Within the context of allergies, NKT cells were shown to participate in Th2 97 
responses through a CD1d-dependent mechanism (Mirotti et al., 2013).  98 
 99 
One of the major bottlenecks in the studies of the interaction of natural lipids with the cells 100 
of the human immune system is the lack of human lipid responsive cell lines. In the present 101 
study, we attempted to engineer human TCRs into a stable murine hybridoma cell line 102 
employing well described synthetic TCR sequences and utilizing the widely used marine 103 
sponge glycolipid -galactosylceramide (-GalCer) as an activator (Bai et al., 2012). 104 
Further, our work with murine and human stable DC cell lines has taken the work to 105 
commercial surrogate human T cells (Jurkats). The transient expression in several Jurkat 106 
backgrounds via plasmid or via lentivirus was also analyzed. Thus, the methodology, 107 
results and discussion presented herein will help towards a cell system able to express 108 
human responsive lipid binding TCR sequences. These are important first steps in the 109 
establishment of cell specific lipid responsive libraries for the study of natural lipid 110 
substances.      111 
 112 
1. Material and methods 113 
 114 
1.1 Cell lines 115 
JAWSII a mouse dendritic cell line was purchased from the American Tissue culture 116 
collection (ATCC) (#CRL-11904). DN32.D3 a mouse double negative iNKT hybridoma cell 117 
line was a gift from Professor Albert Bendelac, Howard Hughes Medical Institute, 118 
University of Chicago, USA. Jurkat Lucia cells (human T cell containing NFAT Luciferase 119 
reporter gene) were purchased from InvivoGen. MUTZ3 cells (human DC cell line) and 120 
ACC 35 cells (human urinary bladder carcinoma) were purchased from the Deutsche 121 
Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ), Braunschweig, 122 
Germany (# 295 and 5637 respectively). MUTZ has been reported to express CD1a, 123 
CD1b, CD1c and CD1d (Masterson et al., 2002). 293T cell, a human embryonic Kidney 124 
cell, was purchased from the American Tissue culture collection (ATCC) (#CRL-3216).  125 
Jurkat 76 is a human TCR / null cell line kindly donated by M. Heemskerk (Heemskerk 126 
et al., 2003) that has been reported as a stable recipient for new TCR sequences (Guo et 127 
al., 2016). 128 
 5 
 129 
 130 
1.2 Chemicals 131 
RPMI 1640 media, heat inactivated FBS, opti-MEM, DMEM and -MEM were purchased 132 
from Gibco, UK. Zeocin and blasticidin were purchased from Thermo Fisher Scientific, 133 
UK. -Galactosyl ceramide-KRN7000L was obtained from Tebu-bio Ltd, UK. Murine GM-134 
CSF was purchased from PeproTech, UK. L-α-Lyso phosphatidylethanolamine;, HEPES, 135 
Beta-Mercaptoethanol, Histopaque, Puromycin, Polyethylenimine, TNF-, Ionomycin and 136 
concanavalin A were purchased from Sigma UK. Sulphatide and glucocerebroside were 137 
from Matreya LLC, USA. L--Lysophosphatidyl inositol sodium salt, phosphatidic acid and 138 
-sitosterol were from Fluka, UK. Phorbol 12-myristate was from Invivogen. 3-sn-139 
Phosphatidyl coline from soya bean from BDH, UK. Fugene 6 Transfection Reagent was 140 
bought from Promega, UK. Sodium pyruvate and L-Glutamine were purchased from 141 
Gibco. Polybrene was purchased from Millipore Co EMD. Luciferase substrate QUANTI-142 
Luc was bought from InvivoGen.  143 
 144 
1.3 Antibodies 145 
Anti-V24PE antibodies were from Beckman Coulter. eBioscience Human IL-2 ELISA 146 
Ready-Set-Go Kit was bought from Fisher Scientific. 147 
 148 
1.4 pMJA219 TRBV25/TRAV10 expression plasmid 149 
A synthetic expression DNA plasmid (pMJA219, GenBank MH782476) containing TCR 150 
receptors has been synthesised (Geneart) based on the backbone of the mammalian 151 
expression plasmid pcDNA3.1(+)(Invitrogen). The / TCR sequences used in pMJA219 152 
design have been previously described as -GalCer specific using lipid loaded tetramers 153 
(Brigl et al., 2006). pMJA219 is driven by the bidirectional Cytomegalovirus promoter from 154 
pBI-CMV1 (Clontech) and flanked by the rabbit  -globin and bGH (bovine Growth 155 
Hormone) polyadenylation sequences at the 3’ end of TRBV25 and TRAV10 sequences 156 
respectively. The complete TCR expression plasmid contains the human -GalCer 157 
responsive TRAV10 (clone J3N.5T, GenBank  DQ341448.1)  and TRBV25 (clone BM2a.t, 158 
GenBank DQ341454.1) cDNA complete sequences without introns (Brigl et al., 2006). 159 
pMJA219 carries selectable markers for Ampicillin for E. coli and G418 (Geneticin) for 160 
mammalian cells.  161 
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1.5 Lentivirus expression 163 
The lentivirus expression was carried out using the 3 plasmid second generation system 164 
essentially as described by Roth et al. (Roth et al., 2017). The psPAX2 (packaging) and 165 
pMD2.G (VSV-G expressing envelope) were gifts from Didier Trono (Addgene plasmid 166 
12260 and 12259 respectively). pSin-EF2-Nanog-Pur (target vector) was a gift from 167 
James Thomson (Addgene plasmid 16578). Two target vectors were assembled. 168 
pMJA285 (Genbank MH782473) contained the bidirectional CMV promoter driving 169 
TRAV10 (GenBank DQ341448.1) and TRBV25 (Genbank DQ341454.1) sequences in 170 
opposite orientation as described for the pMJA219, XbaI and SpeI fragment were inserted 171 
into pSin-EF2-Nanog-Pur. pMJA289 (GenBank MH782475) was assembled by PCR 172 
overlapping primers and contained the same TRAV10/TRBV25 constructs in a dicistronic 173 
orientation driven by EF2 promoter and the / TCR sequences separated by the GSG-174 
2A self-cleavage peptide sequence GSGATNFSLLKQAGDVEDNPGP (Liu et al., 2017). 175 
For the transduction, the target cells (Jurkat Lucia or Jurkat 76) were counted. For each 176 
transduction, 105 cells were used. The cell suspension was centrifuged (1000 rpm, 5 min) 177 
in separated tubes and the supernatant was discarded. Cell pellets were resuspended in 178 
2 ml virus supernatant. Polybrene was added at a final concentration of 8 g/ml. The 179 
suspension was transferred into a 6 well plate. The plate was sealed with parafilm 180 
centrifuged for 90 min at 1200 rpm (spin transduction). Afterwards, the cells were carefully 181 
resuspended and incubated for another 6 hours at 37 °C. Subsequently, the cells were 182 
centrifuged and resuspended in fresh Jurkat media. The supernatant was carefully 183 
discarded and inactivated. 48 hours post transfection, the cells were split. Puromycin 184 
antibiotic was added to one well at a final concentration of 0.5 g/ml. One week later, the 185 
cells were tested in a co-culture. Furthermore, the cells were stained with Anti-V24PE 186 
antibodies  and analysed in flow cytometry as described below. 187 
 188 
1.6 Co-culture 189 
DC-lipid load: human DC MUTZ-3 were cultured at 37°C, 5 % CO2 in media containing -190 
MEM with FBS (20%), condition media (5637 cell line supernatant at 20%) and human 191 
GM-CSF (5ng/ml) according to cell culture instructions (DSMZ). Mouse DC JAWSII were 192 
cultured in the same conditions but in -MEM with FBS (20%), supplemented with L-193 
glutamine (4mM) Na-pyruvate (1mM) and murine GM-CSF (5ng/ml). For lipid loading 194 
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MUTZ-3 or JAWII were counted, centrifuged and resuspended in fresh DC media (RPMI 195 
1640, 10% FBS, 1% PenStrep and 5% DMSO) to a final density of 2.5x104 cells/30l and 196 
added onto each well of a 96 well plate. Lipid or α-GalCer was added to MUTZ or JAWSII 197 
cells to a total 50 l/well reaction mixture and incubated for 24h at 37°C, 5 % CO2. 198 
T cell transfection: Jurkat Lucia cells were cultured in Jurkat media (RPMI 1640, 10% FCS 199 
and 100 μg/ml Zeocin) accordingly to the manufacturer’s instructions (InvivoGen). The 200 
media was changed every three days, by switching between media with and without 201 
Zeocin. Jurkat 76 cells were cultured in Jurkat76 media (RPMI 1640, 10% FCS, 1% L-202 
Glut, 1% sodium pyruvate, 1% PenStrep). For transfection, the cells were counted, 203 
centrifuged and resuspended in 100 l/well fresh Jurkat media to a final density of 2x105 204 
cells/well and dispensed onto a 96 well plate. The transfections were performed by the 205 
procedure described in the Fugene 6 Transfection Reagent protocol (Promega,UK). 206 
Briefly, a total of 50 l of transfection reaction was prepared in RPMI media: 3l Fugene 207 
6 reagent was added followed by 1g plasmid DNA and incubated for 30 min RT. Finally, 208 
all transfection reactions were added drop-wise to each well containing Jurkat cells and 209 
incubated for 24h at 37°C, 5 % CO2. 210 
Co-transfection and readout: After 24h the lipid loaded MUTZ3 cells were mixed and 211 
added (50l/well) to transfected Jurkat Lucia cells onto a 200l final reaction containing 212 
2.4x104 DC+ 2x105 T cells) and incubated overnight at 37°C, 5 % CO2. PMA (50ng/ml) 213 
and ionomycin (3g/ml) were used as positive controls to stimulate T cells. After 24h 214 
incubation, the supernatant was harvested, and the secreted luciferase activity measured 215 
by QUANTI-Luc assay containing coelenterazine substrate. For this, 20l of each sample 216 
was transferred onto Optiplate 96 plate, 50l/well QUANTI-Luc added and immediately 217 
measured onto a luminometer (Turner Biosystems) and analysed in MS-Excel. The 218 
remaining supernatant was stored at -20ºC or used in an IL-2 Sandwich ELISA 219 
determination (384 well plate) using HRP and TMB as substrate following the Ready-Set-220 
Go! Kit according to the manufacturer’s instructions (Fisher Scientific). The results were 221 
read at 450 nm using Tecan Infinite M200 PRO plate reader, data collected by Magellan 222 
software and transferred to a MS-Excel spreadsheet for analysis.  223 
 224 
1.7 Flow cytometric analysis 225 
Firstly, cells in each well were harvested into each FACS tubes, 2 ml of PBA (500 ml PBS 226 
containing 30% BSA and 20% Sodium Azide) was added and centrifuged for 5 min at 227 
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300g. Supernatants were discarded, and cell pellet was re-suspended. 5l antibodies (anti 228 
human V24 antibody) were added and incubated at 4°C for 30 min in the dark. 229 
Afterwards, 2 ml of PBA was added to each tube. Supernatants were discarded, pellet re-230 
suspended and cells were fixed in 0.5 ml PBA. Analysis was carried out on the Flow 231 
Beckman Coulter flow cytometer FC500 (Beckman Coulter life Sciences, USA), at the 232 
Flow Cytometry Facility (University of Nottingham). After quantification by FC500 the data 233 
was analysed using Kaluza software (Beckman Coulter). 234 
 235 
 236 
 237 
 238 
2. Results and discussion  239 
 240 
 241 
2.1 Lipid responsive TCR, murine system  242 
 243 
The murine hybridoma cell line DN32.D3, originally described by A. Bendelac (Lantz and 244 
Bendelac, 1994), has been widely used by many groups working with lipid binding and 245 
NKT cell activation. The TCR of DN32.D3 cell line consists of V14 J18 paired with V8, 246 
V7 or V2 and the cell line expresses the NK1.1 marker, an identifier of NK cells. The 247 
characteristics of DN32.D3 cell line have been described in great detail elsewhere 248 
(Jordan-Williams et al., 2013; Kim et al., 2010, 2006). This double negative hybridoma 249 
murine cell line when presented in co-culture to the murine DC cell line JawsII has shown 250 
a sigmoidal IL-2 dose response curve with increasing -GalCer concentration (Figure 1A). 251 
This response is blocked by murine anti-CD1d antibodies, hence CD1d specific, and is 252 
not further amplified by murine anti-CD3/CD28 beads. Furthermore,  the response 253 
seemed to be IL-2 specific as only the IL-2 cytokine was detected, however,a Luminex 254 
panel containing only 6 cytokines (IL-2, 4, 5, 10, 12 and IFN-) was used (results not 255 
shown).  256 
As expected, the dose response curve of DN32.D3 against -GalCer in co-culture is 257 
species-dependent. DN32.D3 showed a higher sensitivity to lower levels of -GalCer 258 
when the glycolipid is presented by the murine JAWSII than when presented by the human 259 
MUTZ3 DC cell lines (Figure 1B). Regarding lipid specificity, DN32.D3 has shown to be 260 
quantitatively specific to -GalCer in the murine JAWSII system (Ghumra and Alcocer, 261 
2017) with a high background response for the other lipids tested (Figure 1A). The human 262 
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DC system MUTZ3, although less sensitive, responded in addition to -GalCer to LPE 263 
and SDS (Figure 1B).    264 
 265 
 266 
Figure 1: α-GalCer dose response of DN32.D3 co-cultured with JAWSII or MUTZ3 cell lines. A) IL-2--267 
GalCer dose response of DN32D3 wild type and transfected DN32.D3 with the plasmid pMJA219 with JAWSII 268 
or MUTZ3 as indicated after 72h 37°C. B) IL-2-lipid specificity response for DN23.D3 and MUTZ3 or JAWSII, 269 
lipids at 1ug/ml for JAWSII and 10ug/ml for MUTZ3. LPE: lyso-Phosphatidyl ethanolamine, PC: phosphatidyl 270 
choline, PA: Phosphatidic acid, LPI: lyso-phosphatidyl innositol. All co-cultures were performed at density of 271 
5x105 cells/well of DN32.D3 and 5x104 cells/well of APC. 272 
 273 
 274 
In an attempt to engineer new functions and humanise DN32.D3, a plasmid (pMJA219) 275 
containing the -GalCer responsive human TRAV10 and TRBV25 sequences was 276 
constructed (Fig 2). The / TCR sequences used in pMJA219 design have been 277 
previously described as -GalCer specific using lipid loaded tetramers (Brigl et al., 2006). 278 
In order to achieve TCR / equimolar expression a mammalian pMJA219 plasmid was 279 
designed that contained the bidirectional CMV promoter driving the TCR sequences. After 280 
transfection and selection for 3 weeks on Gentamicin, FACS analysis using TRAV10 281 
specific human antibodies (V24 sequence) confirmed that 60-80% of pMJA219 DN32.D3 282 
transfected cells have displayed the specific human TRAV10 and none on the controls. 283 
These results confirmed that the bidirectional promoter is functional and that the murine 284 
cell line DN32.D3 can express a human ⍺ chain. However, when the pMJA219 transfected 285 
DN32.D3 cells were co-cultured with the murine DC JawsII they did not show any 286 
 10 
improvement on their sensitivity to detect -GalCer as shown in Figure 1A or to respond 287 
to PMA/ionomycin (not shown). These transfected cells were also irresponsive when co-288 
cultured with the human MUTZ3 system. 289 
 290 
Whether these results were a product of competition with the murine CD3 as suggested 291 
by some authors (Ahmadi et al., 2011) or by mis-pairing with the endogenous murine / 292 
TCR during ER folding (Knies et al., 2016; Sommermeyer et al., 2006) remains to be 293 
clearly demonstrated. What is clear from this exercise is that the over expression of the 294 
human / chains clearly disrupted the function of the endogenous murine chains (Fig 295 
1A).  296 
 297 
Figure 2: Diagrammatic TCR clones designed and constructed for this work. pMJA219 298 
is a mammalian NeoR plasmid (GenBank MH782476) driven by a bi-directional CMV promoter 299 
(pBI-CMV1, Clontech). pMJA285 (GenBank MH782473) is a similar construct but cloned into 300 
the lentivirus pSin-EF2-Nanog, PurR background. pMJA289 is a polycistronic construct into 301 
which the P2A cleavage sequence has been engineered. The AA proteolytic cleavage 302 
sequence of the P2A is indicated in italic. pMJA288 is pSin-EF2-Nanog lentivirus vector used 303 
in the cloning but without any insert.    304 
  305 
2.2 Jurkat Lucia cells 306 
Attempts to disrupt the wild type TCR murine chains from DN32.D3 before the human 307 
TCR transfection were made by CRISPR, but the resulting clones did not show any murine 308 
/ expression (data not shown). None of the DN32.D3 knockout cells produced 309 
significant amounts of IL-2, or responded to PMI/ionomycin, or were affected by the 310 
presence of the human TRAV10/TRBV25 expression construct. This work therefore is not 311 
shown here. It seems that due to its hybridoma nature and after a large number of 312 
passages, DN32.D3 has suffered a great number of recombinations plus cumulative 313 
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mutations that have resulted in an almost unusable cell line as far as expression of new 314 
TCRs is concerned. 315 
A human stable cell line Jurkat Lucia was used instead of the murine DN32.D3. This cell line 316 
contains an inducible secreted coelenterazine luciferase reporter constructs regulated by 317 
human NFAT binding sites. No data is currently available on TCR or indeed CD3 expression 318 
of this particular cell line. pMJA219 was transfected into Jurkat Lucia and TRAV10 expression 319 
was measured by FACS in a time course experiment. (Figure 3A). Poor transfection (a 320 
maximum of only 0.3 %) was observed but further analyses were nevertheless carried out. 321 
The TRAV10/TRBV25 transfected Jurkat Lucia showed higher levels of luminescence 322 
compared to non-transfected cells when co-cultured with the human dendritic cell MUTZ3 323 
loaded with -GalCer (Fig 3B). Whether the APC, in this case MUTZ3, had time and the right 324 
conditions to achieve the optimal maturity was tested by incubation in three different 325 
maturation/conditioning media (M1, M2 and M3) as shown in Figure 3B. As reported these 326 
media contained different amounts of TNF-, IL-4 hGM-CFS and long and short incubations 327 
(Masterson et al., 2002; Ning et al., 2011). From these findings M1 gave the highest signal 328 
and therefore was used throughout the remainder of the study.     329 
 330 
 331 
 332 
 333 
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 334 
Figure 3: Luminescence of co-culture human DC Mutz3 + Jurkat Lucia T cells. A) Time course 335 
experiment showing the stability of the transfected TCR genes encoded by pMJA219 in Jurkat Lucia T 336 
cells as measure by V24 by FACS. B) Luminescence readings of triplicate wells after 24h of co-337 
incubation of MUTZ3 and Jurkat Lucia cells at density of 2x105 each/well at 37°C, 5 % CO2. M1-3 refers 338 
to the maturation treatment that Mutz has undergone. M1=lipid+24h in RPMI 1640, 10% FBS, 1% 339 
PenStrep and 5% DMSO. M2=Lipid+24h in ⍺-MEM 60%, 20%FBS, 100ng/ml hGM-CSF, 10ng/ml IL-4, 340 
75ng/ml TNF-(Ning et al., 2011). M3=lipid+24h in alpha-MEM 60%, 20%FBS, 50ng/ml hGM-CSF, 341 
20ng/ml IL-4, 12ng/ml TNF- (Masterson et al., 2002). I+P=Ionomycin+PMA.    342 
 343 
 344 
These results have demonstrated that the synthetic human  sequences present in the 345 
plasmid pMJA219 were functional, responded to -GalCer and corroborated previous 346 
work by Brigl, van den Elzen et al. (Brigl et al., 2006). These data suggested that the 347 
commercial human Jurkat Lucia cells could be used for a transient expression of human 348 
TCRs in a lipid screening program. The low transfection rate and stability of these cells is 349 
questionable and warrants the need to further this line of investigation. Whether, as 350 
reported (Guo et al., 2016), an over expression of CD3 could bypass the Jurkat’s known 351 
TCR expression bottle neck and improve the functionality of the cell line, remains to be 352 
shown.  353 
 354 
 355 
 356 
2.3 Lentivirus system 357 
One alternative for plasmid driven TCR expression in T lymphocytes is the use of a 358 
lentivirus expression system as previously reported (Zhou and Buchholz, 2013). In this 3 359 
plasmid system the packaging and envelope genes are mixed with the target or transfer 360 
plasmid (3:1:3) and the virus packed in receptor cells. For this, the target plasmid 361 
pMJA285 has been designed and constructed that contained the / TRAV10/TRBV25 362 
sequences and similarly to pMJA219, was driven by the CMV bidirectional promoter 363 
(Figure 2). In another strategy the target plasmid pMJA289 (Figure 2) was produced 364 
containing the / genes in a discistronic configuration separated by the GSG-2A self-365 
cleavage sequence, as described by Liu et al.  (2017). When these viruses containing / 366 
TCR sequences were transfected into the Jurkat Lucia background, the dicistronic 367 
construct showed a higher transfection rate than the CMV construct after 72h, as 368 
monitored by FACS using anti human V24 Ab (Figure 4A). The human TCR expression 369 
achieved with the protease cleavage construct containing the P2A sequence (pMJA289) 370 
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was higher than the CMV bidirectional construct. These results are in agreement with 371 
Thomas et al.,  (2010) who stated that P2A improves the equimolar expression of both 372 
genes as well as leads to higher levels of cell-surface TCRs.  373 
 Interestingly, much higher transfection efficiency with the same virus constructs was 374 
obtained with the cell line Jurkat76 when compared with Jurkat Lucia (Figure 4), 375 
suggesting a more efficient assembling of the TCR/CD3 complex in this cell line. Jurkat 376 
76 is a human TCR / null cell kindly donated by M. Heemskerk (Heemskerk et al., 377 
2003) that has been reported as good and stable recipient for new TCR sequences (Guo 378 
et al., 2016). Thus, the results presented here corroborated the findings from both groups 379 
and suggests that indeed the mispairing of the endogenous / TCR during ER folding in 380 
the presence of the new human TCR sequences impaired the functionality of the lipid 381 
receptors. 382 
Despite the high transfection efficiency, not all the expressed TCRs seemed to be 383 
functional. IL-2 and luciferase release after co-culture with -GalCer were not much 384 
increased when compared to the transient plasmid expression of pMJA219, although the 385 
expression of the new human  sequences in the Jurkat 76 background produced 386 
reliable titration curves (Figure 4B) and reduced the time for obtaining stable lipid 387 
responsive transfected Jurkat cells.  These results ratified the results in Figure 4A and 388 
show a higher response to α-GalCer of J76 than JL when transduced with plasmid 389 
pMJA289.  390 
 391 
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 393 
 394 
 395 
Figure 4: Human V⍺24 expression of lentivirus transfected Jurkat cell lines.  396 
A) Both cell lines, Jurkat Lucia (JL) and Jurkat 76 (JL76) were transfected with fresh produced viruses, 397 
containing the bidirectional CMV (pMJA285) or EF2 promoter + GSG-2A sequences (pMJA289) or 398 
none, maintained in normal T cell media without selection for 72 h and subsequently stained with anti-399 
human-V24 for FACS analyses. % transfection expressed as the fraction of positive labelled/total cells.  400 
B) Titration curve, both cell lines, JL and J76 transduced with pMJA289, were cocultured with Mutz-3 401 
incubated with different concentrations of -GalCer. The supernatant was collected after 24h and IL-2 402 
was measured in triplicate. 403 
 404 
 405 
Furthermore, the different Jurkat Lucia and Jurkat76 cell lines were co-cultured with Mutz3 406 
+ -GalCer and only Mutz3 (Figure 5C Jurkat Lucia, Figure 5D Jurkat 76 background). 407 
JL285 as well as J76 showed a notable activation by -GalCer.  408 
The expression of the human TCR by lentivirus was further monitored by luminescence 409 
and IL-2 expression in the presence of -GalCer. In a time course experiment and as 410 
shown in Figure 5A and B the assay results from the co-culture one to four weeks post-411 
transduction have significantly changed. The difference between the cell lines with 412 
transduced TCR (JL 285 and JL 289) were notable higher compared to JL 288 (p<0.05). 413 
This experiments suggest that there is only a limited time frame the transduced T-cells 414 
can be used. It has been described that after one week, the cells can undergo apoptosis 415 
and may become exhausted and lose functions with repetitive re-stimulations (Zhong et 416 
al., 2010). 417 
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 418 
 419 
Figure 5: Lentiviral expression of luciferase and IL-2 after coculture 420 
The different Jurkat cell lines (JL:Jurkat Lucia and J76: Jurkat 76 TCR null) were transduced with pMJA285, 421 
pMJA288 (no TCR) and pMJA289. Co-culture time experiments were set Mutz3+α-GalCer for 4 weeks. A) 422 
JL time course luminescence reading. B) ibid but IL-2 measurements. C) JL 24h co-culture with Mutz3 +-α-423 
GalCer. D)  ibid using J76 cell line and IL-2 expression.  424 
 425 
3. Conclusions 426 
Taken together these results demonstrated that widely used murine hybridoma cell line 427 
DN32.D3 is unusable as far as expression of new TCR sequences are concerned. The 428 
results also suggested that a commercial human cell line Jurkat Lucia, containing as 429 
reporter the secreted coelenterazine luciferase regulated by human NFAT, is functional 430 
and potentially could be used for a transient expression of human TCRs, in a lipid 431 
screening program. Further, higher transfection efficiencies were obtained with the 432 
lentivirus polycistronic constructs containing the P2A sequence in a TCR / null cell 433 
(Jurkat 76). These results suggest that indeed the mis-pairing of the endogenous / TCR 434 
during ER folding in the presence of the new human TCR sequences impaired the 435 
functionality of the TCR lipid receptors. These are important first steps in the 436 
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establishment of cell specific lipid responsive libraries for the study of natural lipid 437 
substances. 438 
 439 
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